June 2016

Dear Colleague,

This is the second edition of our newsletter titled HER2-Positive Breast Cancer Updates. In the issue, we provide valuable resources that emanated from the recent Annual Meeting of the American Society of Clinical Oncology. Included are articles on such topics as the benefit of neoadjuvant therapy in early-stage HER2-postive breast cancer, the predictive value of pathologic response rate (pcR), and an overview of an investigative trastuzumab biosimilar. Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advanced at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

Heather Greene, MSN, FNP, AOCN®
The West Cancer Center
Memphis, Tennessee  


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.